These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 34237612)

  • 1. How I treat stage II colon cancer patients.
    Taieb J; Karoui M; Basile D
    ESMO Open; 2021 Aug; 6(4):100184. PubMed ID: 34237612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current status on microsatellite instability, prognosis and adjuvant therapy in colon cancer: A nationwide survey of medical oncologists, colorectal surgeons and gastrointestinal pathologists.
    Toh JWT; Mahajan H; Chapuis P; Spring K
    Cancer Rep (Hoboken); 2021 Feb; 4(1):e1297. PubMed ID: 33030308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microsatellite instability and survival after adjuvant chemotherapy among stage II and III colon cancer patients: results from a population-based study.
    Alwers E; Jansen L; Bläker H; Kloor M; Tagscherer KE; Roth W; Boakye D; Herpel E; Grüllich C; Chang-Claude J; Brenner H; Hoffmeister M
    Mol Oncol; 2020 Feb; 14(2):363-372. PubMed ID: 31816156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subgroups and prognostication in stage III colon cancer: future perspectives for adjuvant therapy.
    Auclin E; Zaanan A; Vernerey D; Douard R; Gallois C; Laurent-Puig P; Bonnetain F; Taieb J
    Ann Oncol; 2017 May; 28(5):958-968. PubMed ID: 28453690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Predictive and prognostic value of MSI phenotype in adjuvant colon cancer: Who and how to treat?].
    Zaanan A; Taieb J
    Bull Cancer; 2019 Feb; 106(2):129-136. PubMed ID: 30527814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microsatellite Instability and Adjuvant Chemotherapy in Stage II Colon Cancer.
    Koenig JL; Toesca DAS; Harris JP; Tsai CJ; Haraldsdottir S; Lin AY; Pollom EL; Chang DT
    Am J Clin Oncol; 2019 Jul; 42(7):573-580. PubMed ID: 31166206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant colon cancer chemotherapy: where we are and where we'll go.
    Lombardi L; Morelli F; Cinieri S; Santini D; Silvestris N; Fazio N; Orlando L; Tonini G; Colucci G; Maiello E
    Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S34-41. PubMed ID: 21129608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Classification of early-stage colon cancer with Immunoscore
    Yalcin S; Philip PA; Athanasiadis I; Bazarbashi S; Shamseddine A
    Future Oncol; 2022 Feb; 18(5):613-623. PubMed ID: 34904905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of Adjuvant Chemotherapy in Colon Cancer With Microsatellite Instability: A Large Multicenter AGEO Study.
    Tougeron D; Mouillet G; Trouilloud I; Lecomte T; Coriat R; Aparicio T; Des Guetz G; Lécaille C; Artru P; Sickersen G; Cauchin E; Sefrioui D; Boussaha T; Ferru A; Matysiak-Budnik T; Silvain C; Karayan-Tapon L; Pagès JC; Vernerey D; Bonnetain F; Michel P; Taïeb J; Zaanan A
    J Natl Cancer Inst; 2016 Jul; 108(7):. PubMed ID: 26839356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study.
    Pagès F; André T; Taieb J; Vernerey D; Henriques J; Borg C; Marliot F; Ben Jannet R; Louvet C; Mineur L; Bennouna J; Desrame J; Faroux R; Kirilovsky A; Duval A; Laurent-Puig P; Svrcek M; Hermitte F; Catteau A; Galon J; Emile JF
    Ann Oncol; 2020 Jul; 31(7):921-929. PubMed ID: 32294529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Views of Australian Medical Oncologists Regarding the Use of Mismatch Repair Status to Assist Adjuvant Chemotherapy Recommendations for Patients With Early-Stage Colon Cancer.
    Loh KW; Michael M; Zalcberg JR; Jefford M
    Clin Colorectal Cancer; 2015 Sep; 14(3):192-7. PubMed ID: 26002619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy.
    Kim ST; Lee J; Park SH; Park JO; Lim HY; Kang WK; Kim JY; Kim YH; Chang DK; Rhee PL; Kim DS; Yun H; Cho YB; Kim HC; Yun SH; Lee WY; Chun HK; Park YS
    Cancer Chemother Pharmacol; 2010 Sep; 66(4):659-67. PubMed ID: 20033812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Should adjuvant chemotherapy be recommended to a 75-year-old woman with deficient mismatch repair (dMMR) gene product expression seen in a stage II colon adenocarcinoma with lymphovascular invasion?
    Sorscher S
    Curr Probl Cancer; 2018 Nov; 42(6):601-604. PubMed ID: 30119912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic and predictive significance of MSI in stages II/III colon cancer.
    Saridaki Z; Souglakos J; Georgoulias V
    World J Gastroenterol; 2014 Jun; 20(22):6809-14. PubMed ID: 24944470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thymidilate synthase expression predicts longer survival in patients with stage II colon cancer treated with 5-flurouracil independently of microsatellite instability.
    Donada M; Bonin S; Nardon E; De Pellegrin A; Decorti G; Stanta G
    J Cancer Res Clin Oncol; 2011 Feb; 137(2):201-10. PubMed ID: 20387074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. No time to die: the consensus immunoscore for predicting survival and response to chemotherapy of locally advanced colon cancer patients in a multicenter international study.
    Ascierto PA; Marincola FM; Fox BA; Galon J
    Oncoimmunology; 2020 Oct; 9(1):1826132. PubMed ID: 33194317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer.
    Ribic CM; Sargent DJ; Moore MJ; Thibodeau SN; French AJ; Goldberg RM; Hamilton SR; Laurent-Puig P; Gryfe R; Shepherd LE; Tu D; Redston M; Gallinger S
    N Engl J Med; 2003 Jul; 349(3):247-57. PubMed ID: 12867608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The interaction between BRAF mutation and microsatellite instability (MSI) status in determining survival outcomes after adjuvant 5FU based chemotherapy in stage III colon cancer.
    Chouhan H; Sammour T; Thomas ML; Moore JW
    J Surg Oncol; 2018 Dec; 118(8):1311-1317. PubMed ID: 30399198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival impact of adjuvant chemotherapy in patients with stage IIA colon cancer: Analysis of the National Cancer Database.
    Achilli P; Crippa J; Grass F; Mathis KL; D'Angelo AD; Abd El Aziz MA; Day CN; Harmsen WS; Larson DW
    Int J Cancer; 2021 Jan; 148(1):161-169. PubMed ID: 32638371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microsatellite Instability was not Associated with Survival in Stage III Colon Cancer Treated with Adjuvant Chemotherapy of Oxaliplatin and Infusional 5-Fluorouracil and Leucovorin (FOLFOX).
    Kim JE; Hong YS; Kim HJ; Kim KP; Kim SY; Lim SB; Park IJ; Kim CW; Yoon YS; Yu CS; Kim JC; Kim JH; Kim TW
    Ann Surg Oncol; 2017 May; 24(5):1289-1294. PubMed ID: 27853901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.